The Difference Of Prostate Volume, Prostate Specific Antigen And Eprostate Specific Antigen Density Level Between Tibetan And Han Patients With Prostate Disease In Qinghai

Objective To explore the difference of prostate volume (PV), prostate specific antigen(PSA) and prostate specific antigen density (PSAD) level between Tibetan and Hanpatients with prostate disease in Qinghai.Methods By detecting the Tibetan and Han benign prostatic hyperplasia, prostatecancer patients with serum prostate specific antigen, prostate volume and prostatespecific antigen density in Qinghai, and the data were statistically analyzed; Statisticalmethods: SPSS19.0statistical software for data analysis, the two ethnic serum PSA,PV and PSAD all were shown as means±standard deviation (x±s), two samples arecompared by t test. The inspection standard was α=0.05.Results The results showed there were significant difference of PSA level betweenTibetan and Han patients in PCa and BPH groups (t=-2.806、-2.197, p <0.05), andthe Tibetan patients with PSA levels higher than the Han patients; In the BPH group,Han and Tibetan patients with PV difference was statistically significant (t=-2.586, p<0.05), Tibetan patients with PV higher than the Han Chinese patients; Of PCa group,Han and Tibetan patients with PV difference was not statistically significant (t=-1.945, p>0.05); There were no significant difference of PSAD level between Tibetanand Han patients in PCa and BPH groups (t=-0.581、-1.463, p>0.05).Conclusions In Qinghai, there were significant difference of PSA level betweenTibetan and Han patients in PCa and BPH groups; In the BPH group, Han and Tibetanpatients with PV difference was statistically significant; Of PCa group, Han andTibetan patients with PV difference was not statistically significant; There were nosignificant difference of PSAD level between Tibetan and Han patients in PCa andBPH groups. Therefore, it is necessary to further study in order to develop moresuitable PSA reference ranges for the two ethnic groups in Qinghai region, it will playan important clinical significance in the screening of PCa. In addition, the joint detection of PSA and PSAD would further contribute to the Tibetan patients withprostate disease goodmalignant identify and improve the detection rate of the early,asymptomatic and curable stage PCa patients, thus effectively reducing the overallcase fatality rate of PCa patients.